Welcome to our dedicated page for Stryker SEC filings (Ticker: SYK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Stryker Corporation (NYSE: SYK) SEC filings page on Stock Titan provides access to the company’s official disclosures filed with the U.S. Securities and Exchange Commission. These documents include current reports on Form 8-K, annual and quarterly reports, and other materials that describe Stryker’s financial condition, governance and material events as a global medical technologies company focused on MedSurg, Neurotechnology and Orthopaedics.
Current reports (Form 8-K) play a central role in Stryker’s disclosure practices. For example, the company has filed 8-Ks to furnish press releases announcing second and third quarter 2025 operating results, detailing net sales, segment performance and earnings metrics. Another Form 8-K dated December 4, 2025 reports leadership changes, including the appointment of a President and Chief Operating Officer and a new Group President, Orthopaedics, and summarizes related compensation arrangements.
Through its SEC filings, Stryker also identifies its registered securities and capital structure. Filings list the company’s common stock, traded on the New York Stock Exchange under the symbol SYK, along with multiple series of senior unsecured notes with different maturities that are also listed on the NYSE. These disclosures help investors understand the instruments available for investing in Stryker and the company’s obligations under its notes.
On Stock Titan, Stryker’s filings are updated in step with new submissions to the SEC’s EDGAR system. AI-powered tools summarize key points from lengthy documents, helping readers quickly identify items such as results of operations, leadership changes, segment commentary and descriptions of registered securities. Users can review Stryker’s historical and recent filings to track how the company reports on its MedSurg, Neurotechnology and Orthopaedics businesses, financial performance and governance over time.
Stryker Corp President and COO Spencer S. Stiles reported an acquisition of 14,912 shares of Common Stock as a performance-based award. The shares were earned upon meeting pre-established three-year adjusted diluted net earnings per share and sales performance goals and will vest on March 21, 2026.
After this grant, Stiles directly holds 83,894 Stryker shares and has an additional 1,670 shares held indirectly through a 401(k) plan. This filing reflects executive compensation rather than an open-market stock purchase or sale.
Pierce James Andrew reported acquisition or exercise transactions in this Form 4 filing.
Stryker Corp Group President James Andrew Pierce reported an equity award of 14,912 shares of Common Stock. The shares were granted at no cash cost upon achievement of pre-set three-year earnings per share and sales goals and will vest on March 21, 2026.
After this grant, Pierce directly holds 88,246 common shares. He also reports indirect holdings of 712 shares held by "Son GP", 713 shares held by "Son AP", and 1,595 shares held through a 401(k) account as of the same date.
STRYKER CORP director Ronda E. Stryker reported a bona fide gift of 55,600 shares of common stock on behalf of a revocable trust. The trust held 2,231,173 shares after the gift. Additional indirect holdings were 12,857,163 shares in the L. Lee Stryker Trust and 37,600 shares in the 1988 William D. Johnston Trust, plus 560 shares held directly.
Stryker Corp director Ronda E. Stryker reported several indirect trust transactions in company common stock. A revocable trust associated with her made bona fide gifts of 377,900 shares on February 13, 2026 and 222,300 shares on February 17, 2026, both at a stated price of $0.00 per share.
Separately, on February 17, 2026, the L. Lee Stryker Trust, for which she serves as trustee and her children are beneficiaries, distributed 42,000 shares to beneficiaries’ individual trusts. She disclaims beneficial ownership of the L. Lee Stryker Trust holdings except to the extent of her pecuniary interest.
Greenleaf Trust reports beneficial ownership of 16,801,654 shares of Stryker Corp common stock, representing 4.4% of the class as of 12/31/2025. Greenleaf has sole voting power over 181,176 shares and shared voting power over 16,620,478 shares.
The firm has sole dispositive power over 122,825 shares and shared dispositive power over 16,678,829 shares. It holds these securities in a fiduciary capacity for various trust and investment management customers and states they are held in the ordinary course of business, not to change or influence control of Stryker.
Stryker Corporation reports strong 2025 growth as a global medical technology leader. Net sales reached $25.1 billion, up from $22.6 billion in 2024, led by MedSurg and Neurotechnology at $15.6 billion and Orthopaedics at $9.5 billion. Net earnings were $3.25 billion, or $8.40 diluted EPS.
The company completed roughly $5.0 billion of acquisitions, including Inari Medical, expanding its Vascular portfolio for venous thromboembolism treatment. Stryker invested $1.62 billion in research, development and engineering and ended the year with $4.10 billion in cash and equivalents and $15.9 billion of total debt.
Stryker issued new senior notes totaling $3.0 billion and expanded its revolving credit facility to $3.0 billion maturing in 2030. The company paid $1.28 billion in dividends and employed about 56,000 people worldwide as of December 31, 2025.
Stryker Corporation director Ronda E. Stryker, through a revocable trust, reported a series of open-market sales of Stryker common stock on February 4–5, 2026. The revocable trust sold multiple blocks of shares at weighted average prices ranging from $358.005 to $368.635 per share, as detailed in the footnotes. After these transactions, the revocable trust held 2,207,331 Stryker shares, with additional indirect holdings of 13,578,805 shares by the L. Lee Stryker Trust and 37,600 shares by the 1988 William D. Johnston Trust, plus 560 shares held directly.
Stryker Corporation reported an equity award transaction for VP and Chief Accounting Officer William E. Berry Jr. on February 4, 2026. He received a grant of 797 restricted stock units with no cash price per unit, increasing his directly held common stock to 3,602 shares, plus 615 shares held indirectly through a 401(k) plan.
Each RSU represents a contingent right to receive one share of Stryker common stock and is scheduled to vest in three equal installments on March 21, 2027, March 21, 2028, and March 21, 2029. Berry also received an employee stock option for 2,391 shares at an exercise price of $360.82, which becomes exercisable as to 20% of the option on each of the first five anniversaries of the grant date and expires on February 3, 2036.
Stryker Corporation reported that VP and Chief Commercial Officer Kimberly Ann Montagnino received an employee stock option grant on February 4, 2026. The option covers 1,830 shares of Stryker common stock at an exercise price of $360.82 per share.
The grant was issued under the Stryker Corporation 2011 Long-Term Incentive Plan and is exercisable as to 20% of the option on each of the first five anniversaries of the grant date. Following this award, she directly holds options for 1,830 shares.
Stryker Corporation reported that officer Debra King received a new stock option award. On February 4, 2026, she was granted 3,992 employee stock options with an exercise price of $360.82 per share under the Stryker Corporation 2011 Long-Term Incentive Plan.
The options vest in stages, becoming exercisable as to 20% on each of the first five anniversaries of the grant date, and are scheduled to expire on February 3, 2036. After this grant, King beneficially owns 3,992 derivative securities directly as VP, Chief Digital and Information Officer.